Train Babcock Advisors LLC Reduces Position in AbbVie Inc. (ABBV)

Train Babcock Advisors LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 0.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,415 shares of the company’s stock after selling 85 shares during the quarter. Train Babcock Advisors LLC’s holdings in AbbVie were worth $755,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ABBV. WealthTrust Axiom LLC lifted its holdings in AbbVie by 0.3% during the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after purchasing an additional 15 shares in the last quarter. Abner Herrman & Brock LLC lifted its holdings in AbbVie by 0.3% during the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after purchasing an additional 18 shares in the last quarter. Bollard Group LLC lifted its holdings in AbbVie by 0.5% during the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock valued at $273,000 after purchasing an additional 19 shares in the last quarter. St. Louis Trust Co lifted its holdings in AbbVie by 0.7% during the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after purchasing an additional 23 shares in the last quarter. Finally, Stratford Consulting LLC lifted its holdings in AbbVie by 0.7% during the first quarter. Stratford Consulting LLC now owns 3,959 shares of the company’s stock valued at $258,000 after purchasing an additional 29 shares in the last quarter. 68.52% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/12/train-babcock-advisors-llc-reduces-position-in-abbvie-inc-abbv.html.

Several equities analysts have weighed in on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and set a $85.00 price target on shares of AbbVie in a report on Thursday, August 3rd. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday. Evercore ISI assumed coverage on shares of AbbVie in a report on Wednesday, August 16th. They issued an “outperform” rating and a $95.00 target price on the stock. SunTrust Banks, Inc. reissued a “buy” rating and issued a $95.00 target price on shares of AbbVie in a report on Wednesday, September 13th. Finally, UBS AG downgraded shares of AbbVie from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $79.00 to $92.00 in a report on Monday, September 25th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $93.68.

In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert A. Michael sold 6,699 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $88.00, for a total transaction of $589,512.00. Following the sale, the vice president now directly owns 10,007 shares of the company’s stock, valued at $880,616. The disclosure for this sale can be found here. Insiders have sold 33,299 shares of company stock worth $2,952,243 in the last quarter. Company insiders own 0.23% of the company’s stock.

AbbVie Inc. (NYSE:ABBV) opened at $95.43 on Friday. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.25 and a current ratio of 1.45. AbbVie Inc. has a 1 year low of $58.60 and a 1 year high of $98.26. The firm has a market cap of $152,347.33, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 1.32 and a beta of 1.51.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. During the same quarter in the previous year, the business posted $1.21 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year. equities research analysts expect that AbbVie Inc. will post 5.55 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a dividend of $0.71 per share. This is a boost from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a yield of 2.98%. AbbVie’s payout ratio is 62.29%.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply